<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342939</url>
  </required_header>
  <id_info>
    <org_study_id>MODY-INK</org_study_id>
    <secondary_id>H-1-2010-130</secondary_id>
    <nct_id>NCT01342939</nct_id>
  </id_info>
  <brief_title>Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)</brief_title>
  <official_title>Postprandial Secretion of of Incretin Hormones and Incretin Effect in Patients With Maturity-onset Diabetes of the Young (MODY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the incretin effect and postprandial incretin
      response in patients with MODY2 and MODY3 and a group of matched healthy subjects. In
      sulphonyl urea treated subjects the purpose is also to compare the incretin effect with and
      without treatment. In healthy subjects the purpose is also to investigate the incretin effect
      under increased levels of endogen incretin hormones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of of insulin secretion (AUC) during the experimental days. Furthermore a
      comparison of GIP, GLP1 and glucagon responses as well as plasma glucose levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Incretin effect</measure>
    <time_frame>Within 1 year</time_frame>
    <description>The difference in insulin responses, as assessed by the area under curve (AUC) for plasma insulin and C-peptide concentrations, during the two different glucose stimuli: OGTT and isoglycemic iv glucose infusion aswell as after a test meal in MODY-patients compared to healthy control subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma GLP1 response</measure>
    <time_frame>Within 1 year</time_frame>
    <description>Comparing GLP1 responses of the different experimental days, compared to healthy control subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma GIP response</measure>
    <time_frame>Within 1 year</time_frame>
    <description>Comparing GIP responses of the different experimental days, compared to healthy control subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucagon response</measure>
    <time_frame>Within 1 year</time_frame>
    <description>Comparing glucagon responses of the different experimental days, compared to healthy control subjects.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">31</enrollment>
  <condition>Maturity-onset Diabetes of the Young</condition>
  <arm_group>
    <arm_group_label>MODY2</arm_group_label>
    <description>Also called GCK (glucokinase) MODY. They have a specific mutation in the GCK gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MODY3</arm_group_label>
    <description>Also called HNF1 alfa MODY. They have a specific mutation in the HNF1 alfa gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control subjects</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Glucose Tolerance Test (OGTT)</intervention_name>
    <description>50g waterfree glucose dissolved in 300ml water consumed over 5 min.</description>
    <arm_group_label>MODY2</arm_group_label>
    <arm_group_label>MODY3</arm_group_label>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <other_name>Waterfree glucose, The Pharmacy of the capital region</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>iso glycaemic intravenous (iv) glucose infusion (IIGI)</intervention_name>
    <description>20% glucose</description>
    <arm_group_label>MODY2</arm_group_label>
    <arm_group_label>MODY3</arm_group_label>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <other_name>Glucose infusion, 20%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Meal test</intervention_name>
    <description>Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)</description>
    <arm_group_label>MODY2</arm_group_label>
    <arm_group_label>MODY3</arm_group_label>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <other_name>Nutridrink with cocoa taste (Nutricia, Allerød, Denmark)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones</description>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <other_name>Januvia, 100mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Incretin effect on sulphonyl urea treatment</intervention_name>
    <description>Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.</description>
    <arm_group_label>MODY2</arm_group_label>
    <arm_group_label>MODY3</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Buffy coat
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Genetically well-charaterized MODY2 and MODY3 patients at Hagedorn Research Institute/Steno
        Diabetes Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians above 18 years

          -  BMI &gt; 19 kg/m2

          -  Negative pancreatic beta cell- and glutamate decarboxylase-65(GAD65)- autoantibodies

          -  Normal haemoglobin

          -  Normal bloodpressure

          -  Informed concent

        Exclusion Criteria:

          -  Known liver disease or affected liver enzymes (ALAT/ASAT &gt;2 x upper normal limit)

          -  Nephropathy (see creatinine&gt; 130 μM and / or albuminuria)

          -  Treatment with medications that cannot be discontinued for 12 hours

          -  Any condition that the investigators feel would interfere with trial participation

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Signe H Østoft, MD, phd stud</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Research Division, University Hospital Gentofte, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Research Division, Gentofte University Hospital, Niels Andersens vej 65, opgang 40, 2.</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <last_update_submitted>January 14, 2013</last_update_submitted>
  <last_update_submitted_qc>January 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Signe H Østoft, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Monogenetic diabetes</keyword>
  <keyword>Diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

